Literature DB >> 12735502

When to biopsy and when to stop biopsying.

Bob Djavan1, Mesut Remzi, Michael Marberger.   

Abstract

With the widespread use of serum prostate-specific antigen (PSA) and transrectal ultrasound-guided needle biopsy of the prostate in men with suspected prostate cancer, physicians are faced with the dilemma of treating a patient with a high index of suspicion of prostate cancer but with an initial set of negative biopsies. For the initial biopsy, the optimal number of biopsy cores for detecting prostate cancer in prostate biopsy remains controversial; it is also often unclear who should undergo a repeat prostatebiopsy and when to stop biopsying.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12735502     DOI: 10.1016/s0094-0143(02)00188-x

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  8 in total

Review 1.  [Prostate biopsy: Procedure in the clinical routine].

Authors:  T Enzmann; T Tokas; K Korte; M Ritter; P Hammerer; L Franzaring; H Heynemann; H-W Gottfried; H Bertermann; M Meyer-Schwickerath; B Wirth; A Pelzer; T Loch
Journal:  Urologe A       Date:  2015-12       Impact factor: 0.639

2.  Contemporary pathologic characteristics and oncologic outcomes of prostate cancers missed by 6- and 12-core biopsy and diagnosed with a 21-core biopsy protocol.

Authors:  Idir Ouzaid; Evanguelos Xylinas; Alexandre Campeggi; Andras Hoznek; Dimitri Vordos; Claude-Clément Abbou; Francis Vacherot; Laurent Salomon; Alexandre de la Taille; Guillaume Ploussard
Journal:  World J Urol       Date:  2011-11-25       Impact factor: 4.226

3.  Rational approach to implementation of prostate cancer antigen 3 into clinical care.

Authors:  Rou Wang; Arul M Chinnaiyan; Rodney L Dunn; Kirk J Wojno; John T Wei
Journal:  Cancer       Date:  2009-09-01       Impact factor: 6.860

Review 4.  Pathologic basis of focal therapy for early-stage prostate cancer.

Authors:  Vladimir Mouraviev; Janice M Mayes; Thomas J Polascik
Journal:  Nat Rev Urol       Date:  2009-04       Impact factor: 14.432

5.  Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy.

Authors:  Alexandre Ben Cheikh; Nicolas Girouin; Marc Colombel; Jean-Marie Maréchal; Albert Gelet; Alvine Bissery; Muriel Rabilloud; Denis Lyonnet; Olivier Rouvière
Journal:  Eur Radiol       Date:  2008-10-17       Impact factor: 5.315

6.  Risk of Upgrading from Prostate Biopsy to Radical Prostatectomy Pathology-Does Saturation Biopsy of Index Lesion during Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy Help?

Authors:  Brian P Calio; Abhinav Sidana; Dordaneh Sugano; Sonia Gaur; Mahir Maruf; Amit L Jain; Maria J Merino; Peter L Choyke; Bradford J Wood; Peter A Pinto; Baris Turkbey
Journal:  J Urol       Date:  2018-01-20       Impact factor: 7.450

7.  Imaging and intervention in prostate cancer: Current perspectives and future trends.

Authors:  Sanjay Sharma
Journal:  Indian J Radiol Imaging       Date:  2014-04

8.  False-positive screening results in the Finnish prostate cancer screening trial.

Authors:  T P Kilpeläinen; T L J Tammela; L Määttänen; P Kujala; U-H Stenman; M Ala-Opas; T J Murtola; A Auvinen
Journal:  Br J Cancer       Date:  2010-01-05       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.